188 related articles for article (PubMed ID: 1510451)
1. Pharmacokinetics of meropenem in subjects with various degrees of renal impairment.
Christensson BA; Nilsson-Ehle I; Hutchison M; Haworth SJ; Oqvist B; Norrby SR
Antimicrob Agents Chemother; 1992 Jul; 36(7):1532-7. PubMed ID: 1510451
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment.
Leroy A; Fillastre JP; Borsa-Lebas F; Etienne I; Humbert G
Antimicrob Agents Chemother; 1992 Dec; 36(12):2794-8. PubMed ID: 1482147
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease.
Chimata M; Nagase M; Suzuki Y; Shimomura M; Kakuta S
Antimicrob Agents Chemother; 1993 Feb; 37(2):229-33. PubMed ID: 8452352
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of meropenem in subjects with renal insufficiency.
Leroy A; Fillastre JP; Etienne I; Borsa-Lebás F; Humbert G
Eur J Clin Pharmacol; 1992; 42(5):535-8. PubMed ID: 1607000
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of meropenem and its metabolite in young and elderly healthy men.
Ljungberg B; Nilsson-Ehle I
Antimicrob Agents Chemother; 1992 Jul; 36(7):1437-40. PubMed ID: 1510440
[TBL] [Abstract][Full Text] [Related]
6. Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment.
Rubino CM; Bhavnani SM; Loutit JS; Lohse B; Dudley MN; Griffith DC
Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29311069
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of meropenem and its metabolite ICI 213,689 in healthy subjects with known renal metabolism of imipenem.
Burman LA; Nilsson-Ehle I; Hutchison M; Haworth SJ; Norrby SR
J Antimicrob Chemother; 1991 Feb; 27(2):219-24. PubMed ID: 2055812
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of cefepime dihydrochloride arginine in subjects with renal impairment.
Cronqvist J; Nilsson-Ehle I; Oqvist B; Norrby SR
Antimicrob Agents Chemother; 1992 Dec; 36(12):2676-80. PubMed ID: 1482136
[TBL] [Abstract][Full Text] [Related]
9. A comparison of the pharmacokinetics of meropenem after administration by intravenous injection over 5 min and intravenous infusion over 30 min.
Kelly HC; Hutchison M; Haworth SJ
J Antimicrob Chemother; 1995 Jul; 36 Suppl A():35-41. PubMed ID: 8543497
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics in renally impaired subjects of NXY-059, a nitrone-based, free-radical trapping agent developed for the treatment of acute stroke.
Strid S; Borgå O; Edenius C; Jostell KG; Odergren T; Weil A
Eur J Clin Pharmacol; 2002 Sep; 58(6):409-15. PubMed ID: 12242600
[TBL] [Abstract][Full Text] [Related]
11. Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin.
Dreetz M; Hamacher J; Eller J; Borner K; Koeppe P; Schaberg T; Lode H
Antimicrob Agents Chemother; 1996 Jan; 40(1):105-9. PubMed ID: 8787889
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration.
Ververs TF; van Dijk A; Vinks SA; Blankestijn PJ; Savelkoul JF; Meulenbelt J; Boereboom FT
Crit Care Med; 2000 Oct; 28(10):3412-6. PubMed ID: 11057794
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of ampicillin (2.0 grams) and sulbactam (1.0 gram) coadministered to subjects with normal and abnormal renal function and with end-stage renal disease on hemodialysis.
Blum RA; Kohli RK; Harrison NJ; Schentag JJ
Antimicrob Agents Chemother; 1989 Sep; 33(9):1470-6. PubMed ID: 2817847
[TBL] [Abstract][Full Text] [Related]
14. Meropenem clinical pharmacokinetics.
Mouton JW; van den Anker JN
Clin Pharmacokinet; 1995 Apr; 28(4):275-86. PubMed ID: 7648757
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and safety of iomeprol in healthy volunteers and in patients with renal impairment or end-stage renal disease requiring hemodialysis.
Lorusso V; Taroni P; Alvino S; Spinazzi A
Invest Radiol; 2001 Jun; 36(6):309-16. PubMed ID: 11410750
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of meropenem in patients with renal failure and patients receiving renal replacement therapy.
Thalhammer F; Hörl WH
Clin Pharmacokinet; 2000 Oct; 39(4):271-9. PubMed ID: 11069213
[TBL] [Abstract][Full Text] [Related]
17. The disposition and metabolic fate of 14C-meropenem in man.
Harrison MP; Haworth SJ; Moss SR; Wilkinson DM; Featherstone A
Xenobiotica; 1993 Nov; 23(11):1311-23. PubMed ID: 8310714
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic study of meropenem in healthy beagle dogs receiving intermittent hemodialysis.
Byun SY; Jeong JW; Choi JH; Lee KP; Youn HY; Maeng HJ; Song KH; Koo TS; Seo KW
J Vet Pharmacol Ther; 2016 Dec; 39(6):560-565. PubMed ID: 27302674
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of meropenem in patients with intra-abdominal infections.
Bedikian A; Okamoto MP; Nakahiro RK; Farino J; Heseltine PN; Appleman MD; Yellin AE; Berne TV; Gill MA
Antimicrob Agents Chemother; 1994 Jan; 38(1):151-4. PubMed ID: 8141572
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of nicotine in kidney failure.
Molander L; Hansson A; Lunell E; Alainentalo L; Hoffmann M; Larsson R
Clin Pharmacol Ther; 2000 Sep; 68(3):250-60. PubMed ID: 11014406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
